Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by DJDawgon Jul 04, 2024 11:24am
227 Views
Post# 36118140

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:PP speculation

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:PP speculation
A few add on comments (please correct me if anything I say is incorrect)

Ruvidar is the brand name for tld-1433, for the bladder

My understanding is that Rutherrin is the brand name for tld-1433 combined with transferrin.
Transferrin is a protein that floats around in blood and binds iron. It then presents itself to the outside of a cell. If the cell needs iron it expresses way more of something called transferrin receptor. Cancer cells have been show to have a lot of transferrin receptors as they are trying to grab any iron passing by. TLD-1433, contains ruthenium which is in the same column of the period table as iron. Same column means many similar properties. So transferrin protein seems to happily bind to tld-1433 and then when passing by, the cancer cell would grab it, assuming it is iron. Now it is in the cell. Trojan horsing it I guess.

I believe that the planned way to do this treatment is to premix the transferrin protein with the tld-1433 and then give it. That way already packaged and ready to go rather than depending on the tld-1433 wandering around looking for the patient's transferrin to bind to.

Eog can correct me but my understanding is Rutherrin is tld-1433 packaged together with transferrin to make the treatment drug.

<< Previous
Bullboard Posts
Next >>